Updated Jul 16, 2026 · Last SEC filing 2026-07-01
X4 Pharmaceuticals, Inc (XFOR) has filed 3 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-01. 3 Form 8-K material event filings were reported by XFOR in the last 90 days. 1 Form 144 notices of proposed sale were filed for XFOR stock. InsiderAlpha tracks every XFOR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001501697 |
|---|
| Form 4 filings (90d) | 3 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-01 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer | S — Open-market sale | 8.5K | $4.26 | $36K | SEC | |
| KIRSKE DAVID | Chief Financial Officer | S — Open-market sale | 17.0K | $4.29 | $73K | SEC | |
| Volpone John | President | A — Grant or award | 289.9K | $0.00 | — | SEC | |
| KIRSKE DAVID | Chief Financial Officer | A — Grant or award | 193.3K | $0.00 | — | SEC | |
| Craig Adam R | Executive Chairman | A — Grant or award | 289.9K | $0.00 | — | SEC | |
| WYZGA MICHAEL S | Director | A — Grant or award | 1.5K | $0.00 | — | SEC | |
| MCGIRR DAVID W J | Director | A — Grant or award | 1.5K | $0.00 | — | SEC | |
| Thoren Natasha Fay | Chief Legal Officer | A — Grant or award | 3.3K | $0.00 | — | SEC | |
| Ragan Paula | President and CEO | S — Open-market sale [10b5-1] | 31.9K | $0.39 | $13K | SEC | |
| Ragan Paula | President and CEO | S — Open-market sale [10b5-1] | 31.9K | $0.56 | $18K | SEC | |
| Taveras Arthur | Chief Scientific Officer | S — Open-market sale [10b5-1] | 76.9K | $0.56 | $43K | SEC | |
| Mostafa Adam S. | Chief Financial Officer | S — Open-market sale [10b5-1] | 230.6K | $0.55 | $127K | SEC | |
| Ragan Paula | President and CEO | S — Open-market sale [10b5-1] | 239.4K | $0.55 | $132K | SEC | |
| Baldry Mark | Chief Commercial Officer | S — Open-market sale [10b5-1] | 11.1K | $0.58 | $7K | SEC | |
| DiBiase Mary | Chief Operating Officer | S — Open-market sale [10b5-1] | 67.7K | $0.57 | $38K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for X4 Pharmaceuticals, Inc (XFOR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| KIRSKE DAVID | 2 | $109K |
| Gold Kelly | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in XFOR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live XFOR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.